Evidence map›Paper›PMID 40088374›Full record

ArticleInternational journal of hematology2025

Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.

Toshihide Yoshikawa, Hisashi Ishida, Akihiro Watanabe, Yuki Yuza, Haruko Shima, Masaki Ito, Yukari Sakurai, Dai Keino, Takuya Ichimura, Keisuke Kato and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Toshihide Yoshikawa *Department of Pediatrics, Faculty of Medical Sciences, University of Fukui, Fukui, Japan. ytoshi@ufukui.ac.jp.
Hisashi Ishida *Department of Pediatrics, Okayama University Hospital, Okayama, Japan.
Akihiro WatanabeDepartment of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan.
Yuki YuzaDepartment of Hematology/Oncology, Tokyo Metropolitan Children'S Medical Center, Tokyo, Japan.
Haruko ShimaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Masaki ItoDepartment of Pediatrics, Soma General Hospital, Fukushima, Japan.
Yukari SakuraiDepartment of Pediatrics, Asahikawa Medical University, Asahikawa, Japan.
Dai KeinoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Takuya IchimuraDepartment of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Keisuke KatoDivision of Pediatric Hematology and Oncology, Ibaraki Children'S Hospital, Mito, Japan.
Yuko OsugiDepartment of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
Shosuke SunamiDepartment of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Japan.
Kunihiro ShinodaDepartment of Pediatrics, Gifu Municipal Hospital, Gifu, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Yuri OkimotoDepartment of Hematology/Oncology, Chiba Children'S Hospital, Chiba, Japan.
Chikako TonoDepartment of Nursing Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan.
Hiroyuki ShimadaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Akihiko TanizawaDepartment of Pediatrics, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.ORCID http://orcid.org/0000-0002-0990-2508

Funding

Agency for Medical Research and Development JP17ck0106329Ministry of Health, Labour and Welfare H23-GanRinsho-Ippan-014
6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a rare disease during childhood, and accelerated phase (AP) and blast phase (BP) CML, also called advanced phases, are even rarer. We retrospectively collected and analyzed clinical data of children younger than 20 years with de novo advanced-phase CML between 1996 and 2017 in Japan. Median follow-up time was 8.9 years for AP-CML (n = 15) and 3.7 years for BP-CML (n = 32). The 5-year overall survival (OS) was 93.3% for AP-CML, and 100.0% for patients who received tyrosine kinase inhibitors (TKIs) in first-line therapy (n = 10). Four of the ten patients who received TKIs in first-line therapy remained in molecular remission without transplantation (median follow-up 5.5 years). The 5-year OS of patients with BP-CML was 79.0%, and most patients received chemotherapy before transplantation, with regimen selection based on blast immunophenotype. Furthermore, among patients who received transplantation after TKI therapy, the 5-year OS was 100.0% for AP and 84.8% for BP. In conclusion, our study confirmed excellent outcomes in children with de novo advanced-phase CML, especially in the TKI-era.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdolescentChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantJapanMaleRetrospective StudiesTreatment OutcomeTyrosine Kinase InhibitorsYoung AdultProtein Kinase InhibitorsTyrosine Kinase InhibitorsAdvanced phaseCMLPediatric hematology/oncologyStem cell transplantationTyrosine kinase inhibitor

Identifiers

PMID40088374
PMCPMC12202577

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.